Table 1.
COVID-19 Vaccine Series Completion Stratified by Independent Variables
| Completed COVID-19 Vaccine Series (n = 860) | Did not Complete COVID-19 Vaccine Series (n = 164) | Odds Ratio (95% CI) | P Value | |
|---|---|---|---|---|
| Age, y | 48.4 ± 17.0 | 39.6 ± 14.4 | — | <.01a |
| Male | 442 (51.4) | 98 (60.0) | 1.43 (1.01–2.01) | .04b |
| Race | — | <.01c | ||
| American Indian, Alaskan Native | 6 (0.7) | 1 (0.6) | — | — |
| Asian | 15 (1.7) | 0 (0.0) | — | — |
| Black | 22 (2.6) | 14 (8.5) | — | — |
| Native Hawaiian, Pacific Islander | 1 (0.1) | 0 (0.0) | — | — |
| White | 804 (93.5) | 145 (88.4) | — | — |
| Hispanic/Latino | 25 (2.9) | 10 (6.1) | 2.17 (1.02–4.61) | .04b |
| BMI, kg/m2 | 28.0 ± 6.6 | 28.1 ± 6.5 | — | .94a |
| Current smoking | 50 (5.8) | 17 (10.4) | 1.87 (1.05–3.34) | .03b |
| Charlson comorbidity index | 1.0 (0–2) | 0.0 (0–1) | — | <.01d |
| Rural | 235 (27.4) | 69 (42.7) | 1.95 (1.38–2.75) | <.01b |
| ADI state decile | 2 (1–4) | 4 (2–6) | — | <.01d |
| Crohn’s disease | 464 (54.0) | 91 (55.5) | 1.06 (0.76–1.49) | .7b |
| Duration of IBD diagnosis, y | 11 (5–20) | 8 (4–14) | — | <.01d |
| IBD appointments (2020) | 1 (0–2) | 1 (1–2) | — | .09d |
| IBD appointments (2021) | 1 (1–1) | 1 (0.25–1) | — | .16d |
| Current mesalamine | 317 (36.8) | 51 (31.1) | 0.77 (0.54–1.11) | .16b |
| Current immune-modifying therapy | — | .90c | ||
| Azathioprine or 6-MP monotherapy | 79 (9.2) | 12 (7.3) | — | — |
| Methotrexate monotherapy | 4 (0.5) | 0 (0.0) | — | — |
| Anti-TNF monotherapy | 250 (29.1) | 50 (30.5) | — | — |
| Anti-TNF combination therapye | 66 (7.7) | 10 (6.1) | — | — |
| Vedolizumab therapyf | 80 (9.3) | 18 (11.0) | — | — |
| Ustekinumab therapyg | 47 (5.5) | 11 (6.7) | — | — |
| Current systemic corticosteroids | 60 (7.0) | 20 (12.2) | 1.85 (1.08–3.17) | .02b |
| Current budesonide | 47 (5.5) | 8 (4.9) | 0.89 (0.41–1.91) | .76b |
| Vaccine addressed by IBD provider | 294 (34.2) | 46 (28.0) | 1.33 (0.92–1.93) | .13b |
| Deferred influenza vaccine (2020–2021) | 198 (23.0) | 99 (0.60) | 5.09 (3.59–7.23) | <.01b |
| Documented COVID-19 infectionh | 54 (6.3) | 21 (12.8) | 2.19 (1.28–3.74) | <.01b |
Values are mean ± SD, n (%), or median (interquartile range).
6-MP, 6-mercaptopurine; ADI, Area Deprivation Index; BMI, body mass index; CI, confidence interval; COVID-19, coronavirus disease 2019; IBD, inflammatory bowel disease; TNF, tumor necrosis factor.
Student’s t test.
Mann-Whitney U test.
Chi-square test.
Odds ratio and 95% CI.
Anti-TNF combination therapy defined as combination of anti-TNF agent and azathioprine, 6-MP, or methotrexate.
Vedolizumab therapy defined as vedolizumab with or without azathioprine, 6-MP, or methotrexate.
Ustekinumab therapy defined as vedolizumab with or without azathioprine, 6-mercaptopureine, or methotrexate
Documented COVID-19 infection includes infection both before and after full vaccination, if applicable, prior to August 1, 2021.